Indiana University School of Medicine Indianapolis, Indiana
Ballvé-Lantero Scholar in Oncology Professor, Department of Medicine Co-Director, Simon Cancer Center Breast Cancer Program
Developing new treatments specifically for Black women with breast cancer
A 30-year-old Black woman is twice as likely to die from breast cancer before she reaches age 50 than a 30-year-old white woman. Individual and neighborhood socioeconomic status, access to care, structural racism, and other social determinants of health are factors that impact outcomes. However, disparities persist even when controlling for these variables. Dr. Miller and her team are investigating these disparities to develop therapies specifically for Black women.
Data from the large, annotated collection of breast cancers from Black and white women from the Women’s Circle of Health Study (WCHS) and normal breast tissue from Black donors (Normal Tissue Bank at Indiana University) both point to important differences in immune pathway activation between Black and white women. Dr. Miller and her team identified a unique cell type (the ‘PZP’ cell) that increases inflammation in the normal breast tissue of Black women by producing an inflammatory chemical called IL-6, which has been associated with resistance to chemotherapy and metastasis. The prolonged and heightened inflammatory response in Black women allows tumors to evade immune surveillance, resulting in more aggressive disease. Chronic inflammation ‘exhausts’ the immune system, further exacerbating disparities in outcome. Effective FDA approved IL-6 targeted therapies are already in clinical use for autoimmune diseases, but they have not been studied as a part of breast cancer therapy.
Dr. Miller and her team have launched a clinical trial to compare IL-6 targeted therapy plus chemotherapy to chemotherapy alone in Black and non-Black women with metastatic triple negative breast cancer. The trial began enrolling patients at Indiana University in March 2024 and will expand to other sites later this year. Additionally, they are partnering with patient advocates to launch an awareness campaign and bolster recruitment through social media.
Kathy D. Miller, MD is Professor of Medicine and the Ballvé-Lantero Scholar at Indiana University (IU) School of Medicine. She is also the Associate Director for Clinical Research at the IU Melvin and Bren Simon Cancer Center. Dr. Miller’s career has combined both laboratory and clinical research in breast cancer. She was the chair of the ECOG-ACRIN Breast Core Committee from 2014-2017, leaving that role when she was elected Co-Chair of the National Cancer Institute (NCI) Breast Cancer Steering Committee. She spearheaded efforts with Radiology to expand cancer screening studies at IU.
“If not for BCRF, this trial would be a dream instead of a reality.”
2003
Please remember BCRF in your will planning. Learn More
Leave your mark.
Join the Evelyn H. Lauder Legacy Society with your bequest for research.
